Loading
Loading
Documentation on the most referenced compound combinations in the research community. What each stack contains, why the components are paired, and which mechanisms each covers.
This page documents stacks referenced in the research and biohacking community for educational purposes. It does not constitute medical advice or a protocol recommendation.
π§
Tissue repair with complementary axes
Components
Drives localised angiogenesis and fibroblast migration to injury sites. Acts on the NO pathway to promote vascular repair.
Enables systemic cell migration by sequestering G-actin. Reduces inflammation and promotes muscle and tendon repair throughout the body.
Why this combination
BPC-157 and TB-500 address tissue repair through entirely different mechanisms β one acts locally at the injury site, the other enables body-wide cellular mobilisation. The combination is the most documented pairing in the biohacking recovery community and forms the base for the GLOW and KLOW stacks.
Community adoption
Most widely referenced repair stack in research communities
Both compounds have compelling animal-model data but no completed human RCTs. Research use only.
β¨
Repair + skin quality and anti-aging
Components
Localised angiogenesis and wound repair.
Systemic cell migration and anti-inflammatory recovery.
Extracellular matrix remodelling. Stimulates collagen and elastin synthesis, activates TGF-Ξ², and resets gene expression in ageing cells.
Why this combination
The Glow Stack extends the Wolverine base into skin quality, collagen synthesis, and anti-ageing outcomes. GHK-Cu is the only peptide spanning both mainstream cosmetic skincare and the research community β naturally occurring in human plasma, declining with age, and one of the most biologically active compounds in the catalog. Growing in biohacking and beauty communities.
Community adoption
Growing adoption β particularly in longevity and cosmetic research communities
Products
π¬
Four-axis tissue repair and inflammation management
Components
Localised angiogenesis and injury-site repair.
Systemic cell migration and tendon/muscle recovery.
Collagen synthesis, matrix remodelling, and gene expression restoration.
Ξ±-MSH-derived tripeptide that inhibits NF-ΞΊB signalling and suppresses pro-inflammatory cytokines β removing the inflammatory microenvironment that impairs tissue repair.
Why this combination
The most comprehensive tissue repair stack documented in the community. KPV acts as a fourth axis β rather than building or mobilising tissue, it quiets the inflammatory signalling that can stall or impair repair. By targeting NF-ΞΊB, KPV removes the primary molecular brake on recovery.
Community adoption
Advanced recovery stack β less common than Wolverine/Glow but gaining traction
KPV has no completed human trials. All four compounds are research use only.
π§
Complementary cognitive performance axes
Components
Synthetic ACTH(4-7) analog. Drives BDNF upregulation and dopaminergic activity β stimulating, neuroprotective, focus-enhancing.
Synthetic tuftsin analog. Acts on the GABAergic system to reduce anxiety and stabilise mood β calming and anxiolytic, without sedation.
Why this combination
Semax and Selank were developed by the same research team at the Institute of Molecular Genetics in Moscow in the 1980sβ90s, and are often used together because they target opposite ends of the cognitive spectrum. Semax drives focus and neuroprotection; Selank blunts anxiety without sedation, dependence risk, or cognitive impairment seen with benzodiazepines. Both are registered prescription medicines in Russia.
Community adoption
The most referenced nootropic pairing in biohacking communities
Both have published Russian-language clinical evidence. Western independent replication is limited. Research use only outside Russia.
π
Expression line reduction via synergistic neuromuscular targeting
Components
Inhibits SNARE complex formation, reducing the neuromuscular signalling that causes repetitive facial contractions and expression lines.
Leuphasyl
Mimics enkephalin activity to dampen nerve signalling at the neuromuscular junction β targeting the same acetylcholine pathway as Argireline but at a distinct binding site.
Why this combination
Argireline and Leuphasyl both reduce expression-driven wrinkle depth, but target different steps in the same signalling pathway. The combined effect is stronger than either alone β this is the format most commonly studied in human clinical trials, and the combination found in most commercial anti-aging serums. Topical use only.
Community adoption
Standard formulation in high-end cosmeceutical serums
Clinical trials exist but sample sizes are limited and largely industry-funded. Topical application only.
βοΈ
Dual appetite-control pathways for GLP-1 plateau-breaking
Components
GLP-1 receptor agonist. Delays gastric emptying, reduces appetite via hypothalamic satiety signalling, and improves insulin sensitivity.
Long-acting amylin agonist. Acts on brainstem amylin receptors to independently suppress appetite and slow gastric emptying β a separate pathway to GLP-1.
Why this combination
CagriSema combines two independent satiety pathways β GLP-1 (gut-derived) and amylin (pancreas-derived). Phase 3 data supports the combination achieving greater weight reduction than semaglutide monotherapy, particularly useful for researchers who have observed a plateau on GLP-1 alone. Novo Nordisk is developing this combination as a single-agent clinical product.
Community adoption
Increasingly used in research contexts following GLP-1 monotherapy plateau
Phase 3 clinical data exists for the combination. Off-label use of separate compounds to replicate the combination is common but not equivalent to the clinical formulation. Research use only.
Products
π₯
GH-axis lift with visceral fat targeting
Components
FDA-approved GHRH analog for HIV-associated lipodystrophy. Specifically targets visceral adipose tissue via the GH axis. Longer-acting than CJC-1295 no-DAC.
Selective ghrelin-receptor agonist. Amplifies the GH pulse without affecting cortisol or prolactin β the cleanest hormonal profile of any secretagogue.
Why this combination
Tesamorelin is the only GHRH analog with an FDA approval, making it the most clinically grounded entry on the GH-axis. Pairing it with Ipamorelin adds a ghrelin-receptor layer that amplifies the natural GH pulse β giving a stronger combined effect than either alone. The stack is community-preferred over CJC+Ipa when visceral fat reduction is the primary research objective.
Community adoption
Preferred GH-axis stack when visceral fat reduction is the research focus
Tesamorelin has FDA approval for HIV lipodystrophy. Its off-label pairing with Ipamorelin is a community-derived research pattern, not a clinical protocol. Research use only.
Products
β‘
Cellular bioenergetics from two complementary angles
Components
Concentrates in the inner mitochondrial membrane and supports ATP production by stabilising cardiolipin. FDA-approved in 2025 as FORZINITY for Barth syndrome β the first mitochondria-targeted drug.
Mitochondrial-derived peptide that regulates metabolic flexibility, insulin sensitivity, and exercise response via AMPK and nuclear translocation.
Why this combination
SS-31 and MOTS-c both originate from or act on mitochondria, but through entirely different mechanisms. SS-31 is membrane-structural β it stabilises cardiolipin to maintain mitochondrial integrity and ATP output. MOTS-c is a signalling peptide that moves between mitochondria and the nucleus to regulate metabolic gene expression. Combining them targets cellular bioenergetics at both the structural and regulatory levels.
Community adoption
Emerging longevity stack β less established than healing or GH-axis combinations
SS-31 has FDA approval for one rare disease indication; all other uses are off-label. MOTS-c has limited clinical data. Treat this stack as experimental. Research use only.
π
Synergistic growth hormone release via dual receptor targeting
Components
Synthetic GHRH analog. Stimulates the GHRH receptor on the pituitary to pulse-release growth hormone. Available with DAC (longer half-life) or without DAC (similar to Sermorelin).
Selective ghrelin-receptor agonist. Stimulates GH release without meaningfully affecting cortisol or prolactin β the cleanest hormonal profile of any GH secretagogue.
Why this combination
CJC-1295 and Ipamorelin target entirely separate receptor pathways β GHRH and ghrelin respectively β and produce a synergistic effect on GH secretion that exceeds either peptide alone. This is one of the most documented GH-axis stacks in the longevity and performance community. Both compounds have reached human clinical trial phases.
Community adoption
One of the most popular stacks in longevity and performance research communities
Both compounds have human clinical trial data but are not FDA-approved. Research use only. Note: CJC-1295 with DAC and without DAC have meaningfully different pharmacokinetics.